CD8A and neoplasm: Besides, Qiao (Qiao et al., 2019) generated a Cetuximab-based IL-10 fusion protein (CmAb-(IL10)2) and found that it could prevent CD8+ tumor-infiltrating lymphocyte apoptosis, further revealing that IL-10 could potentiate CD8+ T cell-mediated antitumor immunity.